Research programme: Neurodegenerative disorders therapeutics - Alzheimer's Drug Discovery Foundation/Pfizer Centers for Therapeutic Innovation
Latest Information Update: 28 Nov 2021
At a glance
- Originator Alzheimers Drug Discovery Foundation; Pfizer Centers for Therapeutic Innovation
- Developer Alzheimers Drug Discovery Foundation; Johns Hopkins University School of Medicine; Pfizer Centers for Therapeutic Innovation
- Class Antidementias; Antiparkinsonians; Neuroprotectants; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Alzheimer's disease; Neurodegenerative disorders; Parkinson's disease
Most Recent Events
- 28 Nov 2021 No recent reports of development identified for research development in Neurodegenerative-disorders in USA
- 28 Nov 2021 No recent reports of development identified for research development in Parkinson's-disease in USA
- 28 Mar 2019 No recent reports of development identified for research development in Alzheimer's-disease in USA